Current Oncology Reports

, 20:62 | Cite as

Peritoneal Metastases from Gastrointestinal Cancer

  • Paul H. SugarbakerEmail author
Gastrointestinal Cancers (J Meyer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gastrointestinal Cancers


Purpose of Review

Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation vs. an aggressive approach using cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy must be made. The perioperative chemotherapy may be hyperthermic intraperitoneal chemotherapy (HIPEC) administered in the operating room or early postoperative intraperitoneal chemotherapy (EPIC) administered in the first 4 or 5 postoperative days.

Recent Findings

This decision is dependent on a well-defined group of prognostic indicators. In addition to treatment, the clinical and pathologic features of a primary cancer can be used to select perioperative treatments that may prevent cancer cells within the abdomen and pelvis from progressing to established peritoneal metastases. In some clinical situations with appendiceal and colorectal cancers, the clinical or histopathologic features may indicate that second-look surgery plus perioperative chemotherapy should occur.


Peritoneal metastases should always be considered for treatment or prevention.


Peritoneal metastases Appendiceal cancer Malignant peritoneal mesothelioma Colon cancer Recurrent ovarian cancer Gastric cancer Cancer prevention 


Compliance with Ethical Standards

Conflict of Interest

Paul H. Sugarbaker declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Sugarbaker PH. New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol. 2006;7(1):69–76.CrossRefPubMedGoogle Scholar
  2. 2.
    •• Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928–35. New standard of care for malignant peritoneal mesothelioma. CrossRefPubMedGoogle Scholar
  3. 3.
    Colon Cancer. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 2.2017–March 13, 2017. Accessed at
  4. 4.
    •• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33:1460–6. Importance of normothermic intraperitoneal chemotherapy long-term. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sugarbaker PH, Kwong ML. Regional chemotherapy: possibilities for prevention and treatment of peritoneal metastases from gastric cancer. (In) Management of Gastric Cancer. SMGroup at
  6. 6.
    • Goere D, Passot G, Gelli M, Sugarbaker PH, Glehen O. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperthermia. 2017;33:528–33. Update of treatment of peritoneal metastases from rare cancers. CrossRefGoogle Scholar
  7. 7.
    Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Popovich RP, Moncrief JW, Nolph KD, Ghods AJ, Twardowski ZJ, Pyle WK. Continuous ambulatory peritoneal dialysis. Ann Intern Med. 1978;88:449–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;40:634–56.CrossRefGoogle Scholar
  12. 12.
    Torres IJ, Litterst CL, Guarino AM. Transport of model compounds across the peritoneal membrane in the rat. Pharmacology. 1978;17:330–40.CrossRefPubMedGoogle Scholar
  13. 13.
    • Dedrick RL, Myers CE, Bungay PM, de Vita V Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62, 1:–11. Establishes the pharmacologic rationale for intraperitoneal chemotherapy. Google Scholar
  14. 14.
    Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, et al. Phase 1 and pharmacologic studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980;40:567–72.PubMedGoogle Scholar
  15. 15.
    Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Myers CE. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 1981;41:1916–22.PubMedGoogle Scholar
  16. 16.
    Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita V. High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Cancer Chemother Pharmacol. 1978;1:161–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209–14.PubMedGoogle Scholar
  18. 18.
    McVie JG, Dikhoff T, Van der Heide J, et al. Tissue concentration of platinum after intraperitoneal cisplatinum in patients (PTS). Proc Am Association Cancer Res. 1985;26:162.Google Scholar
  19. 19.
    •• Sugarbaker PH, van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol 2016;7(1):29–44. Defines surgeon’s role in management of peritoneal metastases. Google Scholar
  20. 20.
    Van der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2011;68:147–56.CrossRefPubMedGoogle Scholar
  21. 21.
    Shiu MH, Fortner JG. Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res. 1980;40:4081–4.PubMedGoogle Scholar
  22. 22.
    Meyer JL, Kapp DS, Fessenden P, Hahn GH. Hyperthermic oncology: current biology, physics and clinical results. Pharmac Ther. 1989;42:251–88.CrossRefGoogle Scholar
  23. 23.
    • Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256–60. The first HIPEC. Google Scholar
  24. 24.
    Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res. 1980;44:1840–2.Google Scholar
  25. 25.
    Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. 1988;61:232–237.Google Scholar
  26. 26.
    Fujimura T, Yonemura Y, Muraoka K, Takamura H, Hirono Y, Sahara H, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg. 1994;18:150–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1998;85:529–34.CrossRefGoogle Scholar
  28. 28.
    Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.CrossRefPubMedGoogle Scholar
  29. 29.
    Feingold PL, Kwong MLM, Sabesan A, Sorber R, Rudloff U. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time? J Gastrointest Oncol. 2016;7:87–98.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology. 2001;48:1776–82.PubMedGoogle Scholar
  31. 31. [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 June 13. Identifier NCT01882933, D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma (GASTRICHIP); [cited 2017 April 22]; Available from:
  32. 32.
    Quirke P, Sebag-Montefiore D, Steele R, et al. Local recurrence after rectal cancer resection is strongly related to the plane of the surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial. J Clin Oncol. 2006;24:article 3512.CrossRefGoogle Scholar
  33. 33.
    Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–82.CrossRefPubMedGoogle Scholar
  34. 34.
    West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol. 2010;28(2):272–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Sugarbaker PH. Colorectal cancer metastases, a surgical perspective. (In) Masters G (Ed). Surg Oncol Clin N Am. 2013;22(2):289–98.CrossRefPubMedGoogle Scholar
  36. 36.
    •• Honore C, Gelli M, Francoul J, et al. Ninety percent of the adverse outcomes in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer? Int J Hyperth 2017;33(5):505–10. Defines parameters for preventive treatments. Google Scholar
  37. 37.
    Honore C, Goere D, Souadka A, Dumont F, Elias D. Definition of patient presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–92.CrossRefPubMedGoogle Scholar
  38. 38.
    Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy (EPIC). Br J Surg 1989;76:1082–1090.Google Scholar
  39. 39.
    Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacologic studies. Cancer Res. 1990;50:5790–4.PubMedGoogle Scholar
  40. 40.
    Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43(Suppl):S15–25.CrossRefPubMedGoogle Scholar
  41. 41.
    Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: a comparison of concomitant versus delayed management. Dis Colon Rectum. 2000;43:1341–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Tentes AA. Preliminary results with the use of hyperthermic intraoperative intraperitoneal chemotherapy or systemic chemotherapy in high-risk colorectal cancer patients. (submitted for publication).Google Scholar
  44. 44.
    Noura S, Ohue M, Shingai T, Kano S, Ohigashi H, Yano M, et al. Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol. 2011;18:396–404.CrossRefPubMedGoogle Scholar
  45. 45.
    Braam HJ, Boerma D, Wiezer MJ, van Ramshorst. Hyperthermic intraperitoneal chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment. Eur J Surg Oncol 2013;39:988–993.Google Scholar
  46. 46.
    Sammartino P, Sibio S, Accarpio F, Di Giorgio A. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Color Dis. 2014;29:1081–9.CrossRefGoogle Scholar
  47. 47.
    Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg. 2001;25:985–90.CrossRefPubMedGoogle Scholar
  48. 48.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, de Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.CrossRefPubMedGoogle Scholar
  49. 49.
    Sugarbaker PH, van der Speeten K, Stuart OA, Chang D, Mahteme H. Patient- and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. (In) Sugarbaker PH (Ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. Cine-Med Publishing: Woodbury, CT, 2012, pp. 183–206.Google Scholar
  50. 50.
    Tanis PJ, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Adjuvant HIPEC in High Risk Colon Cancer (COLOPEC). In: [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 September 19]. Available from: NLM Identifier: NCT02231086.
  51. 51.
    Sugarbaker PH, Sammartino P, Tentes AA. Proactive management of peritoneal metastases from colorectal cancer: the next logical step toward optimal locoregional control. Colorect Cancer. 2012;1(2):115–23.CrossRefGoogle Scholar
  52. 52.
    Sammartino P, Tentes AA, Sugarbaker PH. Eradication of minimal residual disease in the perioperative period in primary colorectal cancer. Colorectal Cancer. 2015;4:157–66.CrossRefGoogle Scholar
  53. 53.
    Sammartino P, Societa Italiana di Chirurgia Oncologica (SICO). PROMENADE trial (PROactive Management of ENdoperitoneal spreAD in colonic cancer). [cited 2017 September 19].Google Scholar
  54. 54.
    Arjona Sanchez A. Prophylactic HIPEC for cT4 colon cancer (personal communication).Google Scholar
  55. 55.
    Griffen WO, Humphrey L, Sosin H. The prognosis and management of recurrent abdominal malignancies. Curr Probl Surg 1969;Apr:3–41., 6, 1, 43Google Scholar
  56. 56.
    Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985;55:1284–90.CrossRefPubMedGoogle Scholar
  57. 57.
    Sugarbaker PH. Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. Int J Surg Oncol Volume 2011 (2011), Article ID 915078, 8 pages, doi:, 1, 8.
  58. 58.
    • Elias D, Goere D, Di Pietrantonio, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008;247;3:445–450. Established parameters for second-look surgery. Google Scholar
  59. 59.
    Delhorme JB, Triki E, Romain B, Meyer N, Rohr S, Brigand C. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis. J Visc Surg. 2015;152(3):149–54.CrossRefPubMedGoogle Scholar
  60. 60.
    Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer, rationale and report of early data. Int J Surg Oncol Volume. 2011:161862, 7.
  61. 61.
    • Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42. Procedures that make HIPEC possible for patients with established peritoneal metastases. CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25:389–94.CrossRefPubMedGoogle Scholar
  63. 63.
    Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Sethna KS, Sugarbaker PH. New prospects for the control of peritoneal surface dissemination of gastric cancer using perioperative intraperitoneal chemotherapy. Cancer Therapy. 2004;2:79–84.Google Scholar
  65. 65.
    Sugarbaker PH. Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Cancer Investig. 2005;23:155–72.CrossRefGoogle Scholar
  66. 66.
    • Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15(1):49–58. Established prognostic indicators for peritoneal metastases. Google Scholar
  67. 67.
    da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878–86.CrossRefPubMedGoogle Scholar
  68. 68.
    Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7.CrossRefPubMedGoogle Scholar
  69. 69.
    Lampe B, Kroll N, Piso P, Forner DM, Mallman P. Prognostic significance of Sugarbaker’s peritoneal cancer index for the operability of ovarian carcinoma. Int J Gynecol Cancer. 2015;25:135–44.CrossRefPubMedGoogle Scholar
  70. 70.
    Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):686–91.CrossRefPubMedGoogle Scholar
  71. 71.
    •• Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228–35. Strong data regarding long-term intraperitoneal chemotherapy for malignant peritoneal mesothelioma. CrossRefPubMedGoogle Scholar
  72. 72.
    Sugarbaker PH. Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. (In) Sugarbaker PH (Ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas (Second Edition). Cine-Med Publishers: Woodbury, CT, 2017, pp. 109–32.Google Scholar
  73. 73.
    Gonzalez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH. Malignant transformation of “benign” cystic mesothelioma of the peritoneum. J Surg Oncol. 2002;79(4):243–51.CrossRefPubMedGoogle Scholar
  74. 74.
    Ihemelandu C, Sugarbaker PH. Clinicopathologic and prognostic features in patients with peritoneal metastasis from mucinous adenocarcinoma, adenocarcinoma with signet ring cells, and Adenocarcinoid of the appendix treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(5):1474–80.CrossRefPubMedGoogle Scholar
  75. 75.
    Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Sur Oncol. 2006;32(6):632–6.CrossRefGoogle Scholar
  76. 76.
    Yan TD, Morris DL, Kusamura S, Baratti D, Deraco M. Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol. 2008;98:224–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computer tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72(5):1631–6.CrossRefPubMedGoogle Scholar
  78. 78.
    Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33.CrossRefPubMedGoogle Scholar
  79. 79.
    •• Sugarbaker PH, Sardi A, Brown G, et al. Concerning CT features used to select patients for treatment of peritoneal metastases, a pictoral essay. Int J Hyperth. 2017;33(5):497–504. CT of use in peritoneal metastases for many intraabdominal cancers. CrossRefGoogle Scholar
  80. 80.
    Jacquet P, Jelinek JS, Chang D, Koslowe P, Sugarbaker PH. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg. 1995;181:530–8.PubMedGoogle Scholar
  81. 81.
    Yan TD, Haveric N, Carmignani P, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;15:839–49.CrossRefGoogle Scholar
  82. 82.
    Rivard JD, Temple WJ, McConnell YJ, et al. Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis. Am J Surg. 2014;207:760–5.CrossRefPubMedGoogle Scholar
  83. 83.
    Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134(3):455–61.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Goere D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–64.CrossRefPubMedGoogle Scholar
  85. 85.
    Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.CrossRefPubMedGoogle Scholar
  86. 86.
    Sugarbaker PH, Welch L, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer institute. Surg Oncol Clin N Am. 2003;12(3):605–21.CrossRefPubMedGoogle Scholar
  87. 87.
    Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240(2):275–85.CrossRefGoogle Scholar
  88. 88.
    Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004;14(1):35–41.CrossRefPubMedGoogle Scholar
  89. 89.
    Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer. 1999;35(3):413–9.CrossRefPubMedGoogle Scholar
  90. 90.
    Paul BK, Ihemelandu C, Sugarbaker PH. Prior surgical score: an analysis of the prognostic significance of an initial non-definitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Abstract in Diseases of Colon and Rectum, March 2016.Google Scholar
  91. 91.
    Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am. 2012;21(4):577–97.CrossRefPubMedGoogle Scholar
  92. 92.
    • Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin N Am. 2003;12(3):825–33. First large group of patients showing favorable results. CrossRefPubMedGoogle Scholar
  93. 93.
    Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;22:1570–5.Google Scholar
  94. 94.
    Sugarbaker PH, van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016;7(1):29–44.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous ifosfamide. Int J Surg Oncol Volume 2011, Article ID 185092, 9 pages, doi:, 2011, 1, 9.
  96. 96.
    Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, el Otmany A, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.CrossRefPubMedGoogle Scholar
  97. 97.
    Van Ruth S, Verwaal VJ, Zoetmulder FAN. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12:771–80.CrossRefPubMedGoogle Scholar
  98. 98.
    Sugarbaker PH, Van der Speeten K, Stuart OA, et al. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol. 2011;37:719–26.CrossRefPubMedGoogle Scholar
  99. 99.
    Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.CrossRefPubMedGoogle Scholar
  100. 100.
    Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth. 2007;23:431–42.CrossRefGoogle Scholar
  101. 101.
    Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41:147–54.CrossRefPubMedGoogle Scholar
  102. 102.
    Young JS, Lumsden CE, Stalker AL. The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol. 1950;62:313–33.CrossRefPubMedGoogle Scholar
  103. 103.
    Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 1992;52:487–90.PubMedGoogle Scholar
  104. 104.
    Urano M, Kuroda M, Nishimura Y. Invited review for the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperth. 1999;15:79–107.CrossRefGoogle Scholar
  105. 105.
    Sugarbaker PH, van der Speeten K. An Overview of Peritonectomy, Visceral Resection, and Therapeutic Laparoscopy for Peritoneal Surface Malignancy. (In) Sugarbaker PH (Ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas (Second Edition). Cine-Med Publishers: Woodbury, CT, 2017, pp. 17–46.Google Scholar
  106. 106.
    Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2008;15:542–6.CrossRefPubMedGoogle Scholar
  107. 107.
    Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14(2):484–92.CrossRefPubMedGoogle Scholar
  108. 108.
    Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–7.CrossRefPubMedGoogle Scholar
  109. 109.
    Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31(1):49–54.CrossRefPubMedGoogle Scholar
  110. 110.
    Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229–37.CrossRefPubMedGoogle Scholar
  111. 111.
    Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12(1):65–71.CrossRefPubMedGoogle Scholar
  112. 112.
    Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178–86.CrossRefPubMedGoogle Scholar
  113. 113.
    Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Restrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63–8.CrossRefPubMedGoogle Scholar
  114. 114.
    Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.CrossRefPubMedGoogle Scholar
  115. 115.
    Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.CrossRefPubMedGoogle Scholar
  116. 116.
    Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24(24):4011–9.CrossRefPubMedGoogle Scholar
  117. 117.
    Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol. 2004;10:2727–30.CrossRefPubMedPubMedCentralGoogle Scholar
  118. 118. [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 June 13. Identifier NCT01882933, D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma (GASTRICHIP); [cited 2017 September 20]; Available from:

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Center for Gastrointestinal MalignanciesMedStar Washington Hospital CenterWashingtonUSA

Personalised recommendations